评论：对于因COVID-19低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率，且不会增加感染风险。 - Suppr | 超能文献

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.

作者信息

Bissell Brittany D, Mefford Breanne, Donaldson J Chris

出版信息

Ann Pharmacother. 2022 Apr;56(4):505-506. doi: 10.1177/10600280211036040. Epub 2021 Jul 30.

DOI:10.1177/10600280211036040

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.评论：对于因COVID-19低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率，且不会增加感染风险。

Ann Pharmacother. 2022 Apr;56(4):505-506. doi: 10.1177/10600280211036040. Epub 2021 Jul 30.

2

Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.回复：对于因 COVID-19 低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率且不增加感染风险。

Ann Pharmacother. 2022 Apr;56(4):507-508. doi: 10.1177/10600280211036047. Epub 2021 Jul 30.

3

Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.COVID-19 低氧性呼吸衰竭住院患者使用低剂量托珠单抗联合大剂量皮质类固醇治疗可改善死亡率而不增加感染风险。

Ann Pharmacother. 2022 Mar;56(3):237-244. doi: 10.1177/10600280211028882. Epub 2021 Jun 28.

4

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.在重症 COVID-19 肺炎和中度炎症反应患者中，单独使用皮质类固醇或与托珠单抗联合使用阿那白滞素后的情况。一项回顾性队列研究：评论

Intern Emerg Med. 2021 Jun;16(4):1101-1103. doi: 10.1007/s11739-021-02663-6. Epub 2021 Feb 18.

5

Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.托珠单抗与皮质类固醇联合治疗重症SARS-CoV-2疾病

Med Intensiva (Engl Ed). 2022 May;46(5):285-287. doi: 10.1016/j.medine.2022.02.013. Epub 2022 Feb 24.

6

Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.托珠单抗治疗后血栓炎症生物标志物的变化趋势比严重SARS-CoV2相关呼吸衰竭患者的评分更能预测治疗失败。

Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.

7

Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.托珠单抗并未降低 COVID-19 住院患者的低氧性呼吸衰竭或死亡风险。

Ann Intern Med. 2021 Feb;174(2):JC16. doi: 10.7326/ACPJ202102160-016. Epub 2021 Feb 2.

8

Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).托珠单抗与皮质类固醇的早期联合应用：重症冠状病毒病（COVID）抗炎治疗的升级

Clin Infect Dis. 2021 May 4;72(9):1682-1683. doi: 10.1093/cid/ciaa910.

9

Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.托珠单抗治疗 SARS-CoV-2 相关严重呼吸衰竭患者预后不良的预测因素：一项多中心真实世界研究。

Int Immunopharmacol. 2022 Jun;107:108709. doi: 10.1016/j.intimp.2022.108709. Epub 2022 Mar 18.

10

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.在重度新型冠状病毒肺炎和中度炎症反应患者中，单用皮质类固醇或联合托珠单抗治疗后使用阿那白滞素：一项回顾性队列研究：回复

Intern Emerg Med. 2021 Jun;16(4):1105-1106. doi: 10.1007/s11739-021-02690-3. Epub 2021 Mar 10.